Pacira Pharmaceuticals

According to the ClinicalTrials.gov registry, Pacira Pharmaceuticals is linked to 31 US clinical trials across every stage of research activity. Of those, 5 studies are currently recruiting — about 16% of the sponsor's indexed portfolio — and 25 are already marked complete, representing roughly 81% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Pacira Pharmaceuticals reports 12 late-stage studies (Phase 3 and Phase 4 combined) and 13 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Pacira Pharmaceuticals is Osteoarthritis of the Knee with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Read our methodology — how this data is sourced, computed, and verified.

Browse all → | Rankings →

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Pacira Pharmaceuticals

Trial Pipeline

A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee

Study to Assess the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

ZILRETTA in Subjects With Shoulder Osteoarthritis

Innovations in Genicular Outcomes Registry

Study to Evaluate the Safety and Tolerability of FX201 in Patients with Osteoarthritis of the Knee

Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers

Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL Administered as a Pectoral Plane Block in Women Undergoing Breast Augmentation

Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa), for Postsurgical Analgesia in Subjects Undergoing Bunionectomy

Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee

Study in Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee

PK Study of EXPAREL in Subjects Undergoing Open Spinal Fusion or Reconstructive Surgery

Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty

Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes

Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction

Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty

Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee

Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles

Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device

Pain Control in Bariatric Patients: EXPAREL(R) vs. the On-Q(R) Pain Ball

Study Evaluating the Treatment of Occipital Neuralgia

Probe Configuration and Time-Temperature Dose Ranging for Understanding of Skin Lesion Effects

TAP-patients With Robotic Assisted Lap Prostatectomy

Cryo-Touch II for the Treatment of Wrinkles

Study of the MyoScience Tissue Remodeling Device for Facial Rejuvenation

A Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty

Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty

Phase Distribution

Therapeutic Areas

What the Pipeline for Pacira Pharmaceuticals Shows

Related